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Corticosteroid Use in Traumatic Optic Neuropathy
Sachin Gandhi MD, Shawn Gandhi MSII, Andre Aung MD, Dan Brill MD, Candice Yousif MD, David Goldman MD, Poonam Bansal MD

Department of Ophthalmology
Henry Ford Hospital , Detroit, Michigan

BACKGROUND

Traumatic optic neuropathy is a potentially
visual devastating event caused by acute
injury to the optic nerve from direct or
indirect trauma. We report a case of traumatic
optic neuropathy improved with
corticosteroid use.
CASE REPORT

A 47 year old male presented with decreased
vision of the left eye after falling down the
stairs. Exam showed a vision of no light
perception in the left eye, 4+ relative afferent
pupillary defect, and a normal fundus exam.
Computed tomography (CT) orbit showed
displaced acute fracture of the medial wall and
roof of the left orbit as well as a fracture of the
left optic canal concerning for optic nerve
compromise. This clinical picture was likely
traumatic optic neuropathy. Patient was started
on IV Solumedrol 30 mg/kg loading dose,
followed by 5.4 mg/kg q 6 hours for 48 hours.
He was also started on brimonidine to help
improve optic nerve perfusion although his
intraocular pressure was normal at 17. On Day
12, it was noted his vision improved to count
fingers from not even being able to see light. At
5 weeks, patient’s vision continuing to be count
fingers and his optic nerve developed temporal
optic nerve pallor. At 4 months, his vision was
also count fingers and his left optic nerve
progressed to show diffuse optic nerve pallor.

Figure 1: Fundus photo showing temporal optic
nerve pallor and OCT confirming nerve fiber layer
damage temporally.

Discussion
Steroids are thought to reduce edema to help reduce optic
nerve damage. Research thus far has been inconclusive
about the use of corticosteroid use in traumatic optic
neuropathy (TON). Levin studied visual outcomes in cases
of TON treated by corticosteroids, orbital decompression
surgery, or observation and showed no statistical
difference.2 However, the study was limited as the number
of eyes in study total was 127. As patient had no
contraindication to steroids in our case, we thought giving
corticosteroids had more potential benefits than harm. Of
note, the CRASH trial did show higher risk of death than the
placebo group so consideration of steroids should be
individualized to the patient. 1

CONCLUSION

• Traumatic optic neuropathy usually presents
with decreased vision, significant relative
afferent pupillary defect, and an initial normal
fundus exam
• Order CT scan of the head and orbit with both
coronal and axial views with 1 mm cuts
• There is currently no definitive treatment, but
corticosteroids should be considered in the
right settings
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Figure 2: CT scan shows a fracture of the medial wall of
the optic canal.
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